Incyte, a biopharmaceutical company, agreed to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company, for $380m. “This acquisition complements our current portfolio, providing us the opportunity to further enhance treatment options for people with vitiligo, leveraging the expertise we established in the Dermatology space through our successful launch of Opzelura™ (ruxolitinib) Cream. People living with immune-mediated dermatologic diseases like vitiligo face significant challenges and we are committed to developing novel therapies like auremolimab, which may address these unmet needs,”Hervé Hoppenot, Incyte CEO.